BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/10/2014 4:07:00 PM | Browse: 1250 | Download: 1100
 |
Received |
|
2013-03-03 15:31 |
|
Peer-Review Started |
|
2013-03-03 18:20 |
 |
First Decision by Editorial Office Director |
|
|
|
Return for Revision |
|
2013-03-14 09:10 |
|
Revised |
|
2013-03-19 02:58 |
|
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2013-05-17 14:30 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2013-05-18 00:23 |
|
Articles in Press |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2013-06-18 12:06 |
|
Publish the Manuscript Online |
|
2013-06-27 17:20 |
| Category |
Infectious Diseases |
| Manuscript Type |
Case Report |
| Article Title |
Coadministration of telaprevir and transcatheter arterial chemoembolization in hepatitis C virus-associated hepatocellular carcinoma
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Harrys A Torres, Parag Mahale, Ethan D Miller, Thein H Oo, Catherine Frenette and Ahmed O Kaseb |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Harrys A Torres, MD, FACP, Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, United States. htorres@mdanderson.org |
| Key Words |
Hepatitis C virus; Cancer; Hepatocellular carcinoma; Transcatheter arterial chemoembolization; Telaprevir; Interactions |
| Core Tip |
This case suggests that therapy for chronic hepatitis C virus (HCV) infection may be given simultaneously with localized chemotherapy in patients with hepatocellular carcinoma (HCC). The use of telaprevir has improved response rates in patients with HCV genotype 1 infections. Substantial number of drug-drug interactions are anticipated with the use of telaprevir, a cytochrome P450 3A and P-glycoprotein substrate and inhibitor. Herein, we describe a patient with HCV-associated HCC treated simultaneously with a telaprevir-containing regimen and localized chemotherapy (transcatheter arterial chemoembolization). No clinically relevant interactions or adverse events developed while on antiviral therapy. |
| Publish Date |
2013-06-27 17:20 |
| Citation |
Torres HA, Mahale P, Miller ED, Oo TH, Frenette C, Kaseb AO. Coadministration of telaprevir and transcatheter arterial chemoembolization in hepatitis C virus-associated hepatocellular carcinoma. World J Hepatol 2013; 5(6): 332-335
|
| URL |
http://www.wjgnet.com/1948-5182/full/v5/i6/332.htm |
| DOI |
http://dx.doi.org/10.4254/wjh.v5.i6.332 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
